First-in-man study with a novel PEGylated recombinant human insulin-like growth factor-I

PEGylation of IGF-I strongly enhances half-life, reduces the negative GH feedback and hypoglycemia potential, and therefore offers a valuable alternative to rhIGF-I in treatment of relevant diseases.